American Bio Medica Corp (ABMC) financial statements (2021 and earlier)

Company profile

Business Address 122 SMITH ROAD
KINDERHOOK, NY 12106
State of Incorp. NY
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 411336156158352
Cash and cash equivalents 411336156158352
Receivables 370452348556672814
Inventory, net of allowances, customer advances and progress billings 8101,0191,4731,5821,7461,722
Inventory 8101,0191,4731,5821,7461,722
Deferred costs      43
Other undisclosed current assets 432997924085
Total current assets: 1,2271,6131,9542,3862,6163,016
Noncurrent Assets
Operating lease, right-of-use asset 73
Property, plant and equipment 644718792824910983
Intangible assets, net (including goodwill) 116123109936765
Intangible assets, net (excluding goodwill) 116123109936765
Deferred costs     190 
Other noncurrent assets 212121211414
Other undisclosed noncurrent assets (3) 1547  
Total noncurrent assets: 8518629379851,1811,062
TOTAL ASSETS: 2,0782,4752,8913,3713,7974,078
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 990840808713740772
Accounts payable 652359374304373410
Accrued liabilities 777575252551
Employee-related liabilities 104278259299292264
Taxes payable 14211589673721
Interest and dividends payable 151311181326
Debt 3887395337148521,837
Deferred compensation liability 191167113   
Other liabilities 522012936639
Other undisclosed current liabilities 665911737155
Total current liabilities: 1,6871,8251,4771,5931,7292,703
Noncurrent Liabilities
Long-term debt and lease obligation 73  753945213
Long-term debt, excluding current maturities    753945213
Operating lease, liability 73
Liabilities, other than long-term debt  719 162192
Due to related parties     124124
Other liabilities  719 3868
Other undisclosed noncurrent liabilities 1,108789772   
Total noncurrent liabilities: 1,1817967917531,107405
Total liabilities: 2,8682,6212,2682,3462,8363,108
Stockholders' equity
Stockholders' equity attributable to parent (790)(146)6231,025961970
Common stock 327323298288260236
Additional paid in capital 21,43721,40421,17021,03720,65620,356
Accumulated deficit (22,554)(21,873)(20,845)(20,300)(19,955)(19,622)
Total stockholders' equity: (790)(146)6231,025961970
TOTAL LIABILITIES AND EQUITY: 2,0782,4752,8913,3713,7974,078

Income statement (P&L) ($ in thousands)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues 3,6553,8724,9145,6096,3177,285
Revenue, net4,9145,6096,3177,285
Cost of revenue (2,471)(2,584)(2,917)(3,119)(3,462)(4,223)
Cost of goods and services sold   (2,917)(3,119)(3,462)(4,223)
Gross profit: 1,1841,2881,9972,4902,8553,062
Operating expenses (1,777)(2,050)(2,308)(2,747)(3,081)(3,320)
Other undisclosed operating income      41
Operating loss: (593)(762)(311)(257)(226)(217)
Nonoperating income (expense) (93)(264)(234)(84)10114
Other nonoperating income (expense) (93)(264)(234)(84)10214
Interest and debt expense (265)(284)(272)(284)(206)(244)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes 265284272284 (41)
Loss from continuing operations before income taxes: (686)(1,026)(545)(341)(331)(488)
Income tax expense (benefit) 5(2) (4)(2)(2)
Net loss available to common stockholders, diluted: (681)(1,028)(545)(345)(333)(490)

Comprehensive Income ($ in thousands)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss: (681)(1,028)(545)(345)(333)(490)
Comprehensive loss, net of tax, attributable to parent: (681)(1,028)(545)(345)(333)(490)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: